Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Aug;78(8):5132–5136. doi: 10.1073/pnas.78.8.5132

Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

J A Streifel, S B Howell
PMCID: PMC320347  PMID: 6975478

Abstract

Isobologram analysis was used to examine the interaction between 1-beta-D-arabinofuranosylcytosine (Ara-C), thymidine (dThd), and hydroxyurea. All three pairs of drugs, as well as the triple combination, were synergistic against a human B cell line in vitro across a broad range of concentrations. Synergy was associated with an increase in the Ara-C nucleotide pool and Ara-C triphosphate concentration. dThd increased, and hydroxyurea decreased, the incorporation of Ara-C into trichloroacetic acid-insoluble macromolecules per unit time. Hydroxyurea was more effective than dThd at equimolar concentrations in increasing the acid-soluble Ara-C pool. Maximal stimulation of Ara-C triphosphate formation by dThd occurred at 1 mM and was associated with reduction of the deoxycytidine triphosphate pool to 31% of control. At the same concentration, hydroxyurea increased Ara-C triphosphate formation to a greater extent but increased deoxycytidine triphosphate to 116% of control. When tested at clinically achievable concentrations on blasts from patients with acute leukemia, hydroxyurea increased the Ara-C nucleotide pool in all six cases studied, whereas dThd decreased the Ara-C nucleotide pool. These results indicate that in SB cells dThd and hydroxyurea work by different mechanisms to augment the Ara-C nucleotide pool and that hydroxyurea may be more effective than dThd as a modulator of Ara-C activity in patients with acute leukemia.

Full text

PDF
5132

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams R. L., Berryman S., Thomson A. Deoxyribonucleoside triphosphate pools in synchronized and drug-inhibited L 929 cells. Biochim Biophys Acta. 1971 Jul 29;240(4):455–462. doi: 10.1016/0005-2787(71)90702-7. [DOI] [PubMed] [Google Scholar]
  2. Atkin C. L., Thelander L., Reichard P., Lang G. Iron and free radical in ribonucleotide reductase. Exchange of iron and Mössbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme. J Biol Chem. 1973 Nov 10;248(21):7464–7472. [PubMed] [Google Scholar]
  3. Berenbaum M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol. 1977 Apr;28(1):1–18. [PMC free article] [PubMed] [Google Scholar]
  4. Bjursell G., Reichard P. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J Biol Chem. 1973 Jun 10;248(11):3904–3909. [PubMed] [Google Scholar]
  5. Bodey G. P., Freireich E. J., Monto R. W., Hewlett J. S. Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep. 1969 Feb;53(1):59–66. [PubMed] [Google Scholar]
  6. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  7. Cadman E. C., Dix D. E., Handschumacher R. E. Clinical, biological, and biochemical effect of pyrazofurin. Cancer Res. 1978 Mar;38(3):682–688. [PubMed] [Google Scholar]
  8. Cadman E., Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest. 1979 Sep;64(3):788–797. doi: 10.1172/JCI109525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chabner B. A., Johns D. G., Coleman C. N., Drake J. C., Evans W. H. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest. 1974 Mar;53(3):922–931. doi: 10.1172/JCI107633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chou T. C., Arlin Z., Clarkson B. D., Phillips F. S. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res. 1977 Oct;37(10):3561–3570. [PubMed] [Google Scholar]
  11. Clarkson B. D., Dowling M. D., Gee T. S., Cunningham I. B., Burchenal J. H. Treatment of acute leukemia in adults. Cancer. 1975 Aug;36(2):775–795. doi: 10.1002/1097-0142(197508)36:2+<775::aid-cncr2820360824>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  12. Clarkson J. M. Enhancement of repair replication in mammalian cells by hydroxyurea. Mutat Res. 1978 Nov;52(2):273–284. doi: 10.1016/0027-5107(78)90148-3. [DOI] [PubMed] [Google Scholar]
  13. Cohen S. S. The lethality of aranucleotides. Med Biol. 1976 Dec;54(5):299–326. [PubMed] [Google Scholar]
  14. Danhauser L. L., Rustum Y. M. Effect of thymidine on the toxicity, antitumor activity, and metabolism of 1-beta-D-arabinofuranosylcytosine in rats bearing a chemically induced colon carcinoma. Cancer Res. 1980 Apr;40(4):1274–1280. [PubMed] [Google Scholar]
  15. Drahovsky D., Kreis W. Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacol. 1970 Mar;19(3):940–944. doi: 10.1016/0006-2952(70)90259-5. [DOI] [PubMed] [Google Scholar]
  16. Durham J. P., Ives D. H. Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation. Mol Pharmacol. 1969 Jul;5(4):358–375. [PubMed] [Google Scholar]
  17. Durham J. P., Ives D. H. Deoxycytidine kinase. II. Purification and general properties of the calf thymus enzyme. J Biol Chem. 1970 May 10;245(9):2276–2284. [PubMed] [Google Scholar]
  18. Engström Y., Eriksson S., Thelander L., Akerman M. Ribonucleotide reductase from calf thymus. Purification and properties. Biochemistry. 1979 Jul 10;18(14):2941–2948. doi: 10.1021/bi00581a004. [DOI] [PubMed] [Google Scholar]
  19. Ensminger W. D., Frei E. High-dose intravenous and hepatic artery infusions of thymidine. Clin Pharmacol Ther. 1978 Nov;24(5):610–615. doi: 10.1002/cpt1978245610. [DOI] [PubMed] [Google Scholar]
  20. Eriksson S., Thelander L., Akerman M. Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry. 1979 Jul 10;18(14):2948–2952. doi: 10.1021/bi00581a005. [DOI] [PubMed] [Google Scholar]
  21. Frei E., 3rd, Bickers J. N., Hewlett J. S., Lane M., Leary W. V., Talley R. W. Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res. 1969 Jul;29(7):1325–1332. [PubMed] [Google Scholar]
  22. Furth J. J., Cohen S. S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res. 1968 Oct;28(10):2061–2067. [PubMed] [Google Scholar]
  23. Garrett C., Santi D. V. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem. 1979 Nov 1;99(2):268–273. doi: 10.1016/s0003-2697(79)80005-6. [DOI] [PubMed] [Google Scholar]
  24. Graham F. L., Whitmore G. F. Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res. 1970 Nov;30(11):2636–2644. [PubMed] [Google Scholar]
  25. Grant S., Lehman C., Cadman E. Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure. Cancer Res. 1980 May;40(5):1525–1531. [PubMed] [Google Scholar]
  26. Grindey G. B., Wang M. C., Kinhan J. J. Thymidine induced perturbations in ribonucleoside and deoxyribonucleoside triphosphate pools in human leukemic CCRF-CEM cells. Mol Pharmacol. 1979 Sep;16(2):601–606. [PubMed] [Google Scholar]
  27. Harris A. W., Reynolds E. C., Finch L. R. Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1979 Feb;39(2 Pt 1):538–541. [PubMed] [Google Scholar]
  28. Ho D. H., Carter C. J., Brown N. S., Hester J., McCredie K., Benjamin R. S., Freireich E. J., Bodey G. P. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells. Cancer Res. 1980 Jul;40(7):2444–2446. [PubMed] [Google Scholar]
  29. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  30. Howell S. B., Chu B., Mendelsohn J., Carson D. A., Kung F. H., Seegmiller J. E. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. J Natl Cancer Inst. 1980 Aug;65(2):277–284. [PubMed] [Google Scholar]
  31. Howell S. B., Taetle R., Mendelsohn J. Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia. Blood. 1980 Mar;55(3):505–510. [PubMed] [Google Scholar]
  32. Ives D. H., Durham J. P. Deoxycytidine kinase. 3. Kinetics and allosteric regulation of the calf thymus enzyme. J Biol Chem. 1970 May 10;245(9):2285–2294. [PubMed] [Google Scholar]
  33. Jackson R. C. The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluorodeoxyuridine, and 3-deazauridine. J Biol Chem. 1978 Oct 25;253(20):7440–7446. [PubMed] [Google Scholar]
  34. KIM J. H., EIDINOFF M. L. ACTION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE ON THE NUCLEIC ACID METABOLISM AND VIABILITY OF HELA CELLS. Cancer Res. 1965 Jun;25:698–702. [PubMed] [Google Scholar]
  35. Kessel D., Hall T. C., Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science. 1967 Jun 2;156(3779):1240–1241. doi: 10.1126/science.156.3779.1240. [DOI] [PubMed] [Google Scholar]
  36. Khym J. X. An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers. Clin Chem. 1975 Aug;21(9):1245–1252. [PubMed] [Google Scholar]
  37. Krakoff I. H., Brown N. C., Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 1968 Aug;28(8):1559–1565. [PubMed] [Google Scholar]
  38. Lauzon G. J., Paran J. H., Paterson A. R. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells. Cancer Res. 1978 Jun;38(6):1723–1729. [PubMed] [Google Scholar]
  39. Lowe J. K., Grindey G. B. Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells. Mol Pharmacol. 1976 Jan;12(1):177–184. [PubMed] [Google Scholar]
  40. Mills-Yamamoto C., Lauzon G. J., Paterson A. R. Toxicity of combinations of arabinosylcytosine and 3-deazauridine toward neoplastic cells in culture. Biochem Pharmacol. 1978 Jan 15;27(2):181–186. doi: 10.1016/0006-2952(78)90298-8. [DOI] [PubMed] [Google Scholar]
  41. Momparler R. L., Brent T. P., Labitan A., Krygier V. Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol Pharmacol. 1971 Jul;7(4):413–419. [PubMed] [Google Scholar]
  42. Momparler R. L. Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun. 1969 Feb 21;34(4):464–471. doi: 10.1016/0006-291x(69)90405-7. [DOI] [PubMed] [Google Scholar]
  43. Momparler R. L., Fischer G. A. Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem. 1968 Aug 25;243(16):4298–4304. [PubMed] [Google Scholar]
  44. Momparler R. L. Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol. 1972 May;8(3):362–370. [PubMed] [Google Scholar]
  45. Müller W. E., Yamazaki Z. I., Sögtrop H. H., Zahn R. K. Action of 1- -D-arabinofuranosylcytosine on mammalian tumor cells. 2. Inhibition of mammalian and oncogenic viral polymerases. Eur J Cancer. 1972 Aug;8(4):421–428. doi: 10.1016/0014-2964(72)90127-2. [DOI] [PubMed] [Google Scholar]
  46. Plagemann P. G., Erbe J. The deoxyribonucleoside transport systems of cultured Novikoff rat hepatoma cells. J Cell Physiol. 1974 Jun;83(3):337–343. doi: 10.1002/jcp.1040830303. [DOI] [PubMed] [Google Scholar]
  47. Plagemann P. G., Marz R., Wohlhueter R. M. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res. 1978 Apr;38(4):978–989. [PubMed] [Google Scholar]
  48. Preisler H. D., Rustum Y., Henderson E. S., Bjornsson S., Creaven P. J., Higby D. J., Freeman A., Gailani S., Naeher C. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood. 1979 Mar;53(3):455–464. [PubMed] [Google Scholar]
  49. REICHARD P., CANELLAKIS Z. N., CANELLAKIS E. S. Studies on a possible regulatory mechanism for the biosynthesis of deoxyribonucleic acid. J Biol Chem. 1961 Sep;236:2514–2519. [PubMed] [Google Scholar]
  50. Reichard P. Control of deoxyribonucleotide synthesis in vitro and in vivo. Adv Enzyme Regul. 1972;10:3–16. doi: 10.1016/0065-2571(72)90003-9. [DOI] [PubMed] [Google Scholar]
  51. Reynolds E. C., Harris A. W., Finch L. R. Deoxyribonucleoside triphosphate pools and differential thymidine sensitivities of cultured mouse lymphoma and myeloma cells. Biochim Biophys Acta. 1979 Jan 26;561(1):110–123. doi: 10.1016/0005-2787(79)90495-7. [DOI] [PubMed] [Google Scholar]
  52. Roller B., Cohen G. H. Deoxyribonucleoside triphosphate pools in synchronized human cells infected with herpes simplex virus types 1 and 2. J Virol. 1976 Apr;18(1):58–64. doi: 10.1128/jvi.18.1.58-64.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Royston I., Smith R. W., Buell D. N., Huang E. S., Pagano J. S. Autologous human B and T lymphoblastoid cell lines. Nature. 1974 Oct 25;251(5477):745–746. doi: 10.1038/251745a0. [DOI] [PubMed] [Google Scholar]
  54. Rustum Y. M. Metabolism and intracellular retention of 1-beta-D-arabinofuranosylcytosine as predictors of response of animal tumors. Cancer Res. 1978 Mar;38(3):543–549. [PubMed] [Google Scholar]
  55. Skoog L., Nordenskjöld B. Effects of hydroxyurea and 1-beta-D-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells. Eur J Biochem. 1971 Mar 1;19(1):81–89. doi: 10.1111/j.1432-1033.1971.tb01290.x. [DOI] [PubMed] [Google Scholar]
  56. Smyth J. F., Robins A. B., Leese C. L. The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia. Eur J Cancer. 1976 Jul;12(7):567–573. doi: 10.1016/0014-2964(76)90164-x. [DOI] [PubMed] [Google Scholar]
  57. Thelander L., Reichard P. Reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133–158. doi: 10.1146/annurev.bi.48.070179.001025. [DOI] [PubMed] [Google Scholar]
  58. Walters R. A., Tobey R. A., Ratliff R. L. Cell-cycle-dependent variations of deoxyribonucleoside triphosphate pools in Chinese hamster cells. Biochim Biophys Acta. 1973 Sep 7;319(3):336–347. doi: 10.1016/0005-2787(73)90173-1. [DOI] [PubMed] [Google Scholar]
  59. Zaharko D. S., Bolten B. J., Chiuten D., Wiernik P. H. Pharmacokinetic studies during phase I trials of high-dose thymidine infusions. Cancer Res. 1979 Dec;39(12):4777–4781. [PubMed] [Google Scholar]
  60. Zahn R. K., Müller W. E., Forster W., Maidhof A., Beyer R. Action of 1- -D-arabinofuranosylcytosine on mammalian tumor cells. 1. Incorporation into DNA. Eur J Cancer. 1972 Aug;8(4):391–396. doi: 10.1016/0014-2964(72)90122-3. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES